Baird Financial Group
VKTX icon

Baird Financial Group’s Viking Therapeutics VKTX Stock Holding History

Baird Financial Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
+46,190
New +$1.49M ﹤0.01% 1137
2024
Q4 		– Sell
-13,988
Closed -$886K – 1817
2024
Q3 		$886K Buy
+13,988
New +$821K ﹤0.01% 1215

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Baird Financial Group's VKTX Position: Q2 2026 in Review

Baird Financial Group opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 46,190 shares worth $1.8M. The stake represents ﹤0.01% of the portfolio and ranks #1137 among its holdings. This is a return to the name: Baird Financial Group previously reported a position in VKTX as recently as Q3 2024.

Baird Financial Group first reported a position in VKTX in Q3 2024 and has held it in 2 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Baird Financial Group held 46,190 shares of Viking Therapeutics worth $1.8M as of Q2 2026.
  • Viking Therapeutics was a new Baird Financial Group position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1137 holding.
  • Baird Financial Group first reported a position in Viking Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.